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Abstract
Introduction: Patients with complex sleep apnoea (CompSAS) have obstructive sleep apnoea and experience persistent
central apnoeas when exposed to positive airway pressure. Elevated loop gain is one of the postulated mechanisms of
CompSAS. We speculated that bilevel positive airway pressure — spontaneous (BPAP-S), by producing relative hyperventi-
lation, may more readily produce CompSAS activity than continuous positive airway pressure (CPAP). If found to do so,
a trial of BPAP-S might be a simple way of identifying patients with elevated loop gain who are at risk for CompSAS.
Materials and methods: Thirty-nine patients with complex sleep apnoea were included in the study. Segments of NREM
sleep on CPAP and BPAP-S matched for body position and expiratory airway pressure (“comparison pressure”) were
retrospectively analysed. Correlations between clinical and demographic variables and polysomnographic response to CPAP
and BPAP-S were sought.
Results: There was no difference in any of the polysomnographic indices on CPAP and BPAP-S. In 19 patients the use of
CPAP was associated with lower AHI at the comparison pressure; in 20 patients the opposite was true. No clinical variables
correlated to the differential response to CPAP vs. BPAP-S.
Conclusions: BPAP-S was not more effective than CPAP in stimulating complex sleep apnoea activity.
Key words: complex sleep apnoea, central sleep apnoea, obstructive sleep apnoea, continuous positive airway pressure,
bilevel positive airway pressure, loop gain
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Streszczenie
Wstęp: Zastosowanie terapii stałym dodatnim ciśnieniem dróg oddechowych (CPAP) u chorych na zespół złożonego
bezdechu śródsennego (CompSAS) prowadzi do wystąpienia zaburzeń oddychania typu ośrodkowego. Jednym z podsta-
wowych postulowanych mechanizmów powstawania CompSAS jest zwiększenie loop gain — wzmocnienia pętli sprzęże-
nia — definiowanego jako całkowita odpowiedź układu oddechowego na zaburzenie jego stanu równowagi. Teoretycznie,
zastosowanie terapii aparatem wytwarzającym dwupoziomowe ciśnienie w drogach oddechowych w trybie spontanicz-
nym (BPAP-S), powinno nasilać hiperwentylację i prowadzić do łatwiejszego powstawania fenotypu CompSAS niż CPAP.
Praktyczne potwierdzenie tej teorii pozwoliłoby na łatwiejszą identyfikację osób z wysokim wzmocnieniem pętli sprzęże-
nia, narażonych na CompSAS.
Materiał i metody: Badaniem objęto grupę 39 chorych na CompSAS. Przeprowadzono retrospektywną analizę porów-
nawczą fragmentów snu NREM uzyskanych podczas polisomnografii terapeutycznej (PSG) uzyskanych podczas stosowania
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Introduction
Complex sleep apnoea syndrome (CompSAS)
is a phenotypic designation of central sleep apno-
ea appearing in a patient with obstructive sleep
apnoea upon correction of airway obstruction, typi-
cally with a positive airway pressure (PAP) therapy
[1–3]. This infrequent condition affects 1–5% of pa-
tients with OSA; patients with CompSAS are usual-
ly treated with various forms of PAP therapy, of
which adaptive servoventilation seems to have the
highest immediate and short-term efficacy [4–10].
The aetiology of CompSAS is unknown, and
several mechanisms are likely to contribute to the
appearance of this phenotype. The use of opioids
is associated with central apnoea, Biot’s breathing,
and ataxic breathing; additionally, the sedative
effects of opioids decrease the respiratory drive —
a known protective mechanism against airway col-
lapse [11–13]. The resulting coexistence of obstruc-
tive and central phenomena may produce the com-
plex sleep apnoea phenotype. Congestive heart
failure frequently results in central apnoea with
Cheyne-Stokes pattern, which may give a complex
apnoea phenotype and be difficult to treat [14, 15].
Finally, low arousal threshold may result in sleep
fragmentation and repeated oscillations around the
apnoeic threshold, manifested by frequent central
apnoeas. Loop gain, an engineering term reflecting
the capacity of a feedback-controlled system, has
been used to describe the general propensity of the
respiratory system to cycle between hyperpnoea
and apnoea [16]. Patients with CompSAS have
been postulated to have an elevated loop gain com-
pared to non-CompSAS patients with OSA [17].
Though some patients with OSA cycle be-
tween hyperpnoea and central apnoea just with
clearance of airway obstruction with CPAP (posi-
tive airway pressure), this cycling can be enhan-
ced by increasing the respiratory output following
the patient’s own respiratory effort. This effect is
probably due to the lowering of PaCO2 below the
CPAP i BPAP-S, zgodnych co do pozycji ciała pacjenta i ciśnienia wydechowego („ciśnienie porównawcze”). Poszukiwano
korelacji pomiędzy parametrami klinicznymi, demograficznymi oraz odpowiedzią chorych na CPAP i BPAP-S.
Wyniki: Nie stwierdzono różnic w żadnym parametrze polisomnograficznym pomiędzy segmentami snu podczas próby
stosowania CPAP i BPAP-S. U 19 chorych, wskaźnik bezdechów i spłyceń oddechu (AHI) był niższy podczas leczenia
aparatem CPAP na poziomie ciśnienia porównawczego niż podczas leczenia BPAP-S, zaś u 20 pacjentów obserwowano
odwrotną zależność. Nie stwierdzono korelacji żadnego z badanych parametrów klinicznych ze skutecznością CPAP lub
BPAP-S.
Wnioski: Nie obserwowano zwiększenia częstości wywoływania CompSAS przez BPAP-S w porównaniu z CPAP.
Słowa kluczowe: zespół złożonego bezdechu śródsennego, ośrodkowy bezdech śródsenny, obturacyjny bezdech śródsenny,
stałe dodatnie ciśnienie dróg oddechowych, dwufazowe dodatnie ciśnienie dróg oddechowych, wzmocnienie pętli sprzężenia
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apnoeic threshold, and it has been achieved in
experimental studies by proportional assist venti-
lation (PAV), a technique that augments pressure
support in proportion to the patient’s own respira-
tory effort [18, 19].
Bilevel PAP devices in spontaneous mode
(BPAP-S) with constant pressure support are com-
monly employed in nocturnal hypoventilation and
in patients with OSA who have difficulty tolera-
ting PAP therapy. Since BPAP-S increases tidal
volume for any given respiratory drive, and irre-
spective of this drive, and may thus increase the
minute ventilation and lower PaCO2 (potentially
exposing the individual to the risk of cycling), we
speculated that patients with CompSAS tendency
will indeed have more central apnoea activity
while on BPAP-S than CPAP. If true, such an expo-
sure to BPAP-S during therapeutic testing could
allow for early recognition and shorter evaluation
of CompSAS activity, and could prevent repeated
in-lab testing with different PAP modalities that are
usually necessary in these patients [20].
Materials and methods
The study was approved by the Institutional
Review Board of the NorthShore University Health
System. All patients were referred to a single sle-
ep centre and were evaluated between 11/1/2006
and 12/31/2010 by one of a team of ten sleep board-
certified physicians. Patients underwent a diagno-
stic and therapeutic polysomnogram. If severe sle-
ep apnoea was observed during the diagnostic stu-
dy (apnoea-hypopnea index [AHI] > 30/h) over at
least two hours of recorded sleep, and sufficient time
remained (> 3 hours of expected bed time), the pa-
tient had a PAP titration during the same night
(“split-night protocol”). All therapeutic polysomno-
grams started with CPAP; BPAP-S was applied in
cases of the appearance of complex sleep apnoea,
by the order of the physician, or in cases of poor
CPAP tolerance, by technician’s discretion.
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All studies were performed in compliance
with American Academy of Sleep Medicine
(AASM) standards, were scored according to the
AASM scoring criteria, and read by one of the team
of 10 board-certified or board-eligible sleep physi-
cians. Airflow and respiratory effort were monito-
red using a nasal pressure transducer and respira-
tory impedance plethysmography during the dia-
gnostic study, and using the flow channel from the
CPAP or BPAP plus respiratory impedance plethy-
smography during the positive pressure titration
studies. Hypopnoeas were defined as an abnormal
respiratory event lasting at least 10 seconds with
at least a 30% reduction in thorocoabdominal mo-
vement or airflow as compared to baseline, and
with at least a 4% oxygen desaturation. PAP titra-
tion was performed in accordance with a local pro-
tocol — in cases of residual obstruction, CPAP
pressure was increased by 1 cmH2O every ten mi-
nutes; during BPAP-S titrations, the same proce-
dure was followed for expiratory positive airway
pressure (EPAP). During BPAP-S titrations the in-
spiratory positive airway pressure (IPAP) was ini-
tially set 4–5 cm H2O above EPAP and then incre-
ased as the EPAP was increased, in order to keep
the (IPAP-EPAP, “delta”) difference constant. Du-
ring the BPAP-S studies, if obstruction was suc-
cessfully controlled and hypoxemia remained, an
attempt to increase delta was undertaken. Follo-
wing the evaluation, patients were treated with
PAP modalities at the discretion of their physician.
Objective compliance with the PAP device was
assessed at the first visit at 4–6 weeks of its use.
Patients who did not come for their follow-up ap-
pointment were contacted over the telephone re-
garding their usage. All patients who could not be
contacted or could not supply the compliance card
were treated as non-compliers.
Patients with complex sleep apnoea were inc-
luded in the analysis. “Complex sleep apnoea” was
defined as the development of central sleep apno-
ea or having central apnoea index of more than 5/
/hour or prominent and disruptive Cheyne-Stokes
breathing pattern in a patient with obstructive sle-
ep apnoea. Patients were included in the study if
their supervised PAP titration study contained
two segments, one on CPAP and one on BPAP-S,
of non-rapid eye movement (NREM) sleep of at le-
ast 10 minutes’ duration, matched for pressure
(where continuous PAP on CPAP equalled EPAP
on BPAP-S, called “comparison pressure”) and posi-
tion of sleep. Polysomnograms of thus identified pa-
tients were retrospectively reviewed and polysom-
nographic variables pertaining to sleep segments
spent at comparison pressure (apnoea-hypopnea
index [AHI], central apnoea index [CAI], hypop-
nea index [HI], and arousal index [AI]) were col-
lected. Additionally, individual demographic and
clinical variables were collected.
Continuous data were presented as medians
and interquartile ranges and analysed using ANO-
VA. Discrete data were analysed using Fisher’s
exact test. Correlations were analysed with Pear-
son’s correlation.
Results
Of 72 patients with complex sleep apnoea
identified and considered for the study, 33 were
excluded (16 did not register NREM in the same
body position on both CPAP and BPAP-S, in 7 the
original polysomnogram could not be reviewed,
in 7 patients CPAP and BPAP-S were tried on dif-
ferent nights, and in 3 patients significant resi-
dual obstruction was seen at the comparison pres-
sure), leaving 39 patients included in the analy-
sis. In all cases, the BPAP-S trial followed the
CPAP trial in the course of the polysomnographic
evaluation. Demographic and polysomnographic
data of patients included in the study are presen-
ted in Table 1.
Table 1. Demographic, clinical, and polysomnographic
characteristics of patients with CompSAS (n =
39) included in the analysis. Data are presented
as n (percentage) or medians (interquartile ran-
ge), as appropriate
Tabela 1. Dane demograficzne, kliniczne i polisomnogra-
ficzne chorych z zespołem bezdechu złożonego
(n = 39) poddanych analizie. Dane przedstawio-
no jako n (procent) lub mediany (zakres między-
kwartylowy)
Variable Value
Age (years) 61.0 (50.5–71.5)
Gender (M/F) 27/12
Body mass index [kg/m2] 31.3 (28.7–35.7)
Epworth Sleepiness Scale score 11 (8.5–16)
Congestive heart failure (yes/no) 10 (25.6%)
Opioid use (yes/no) 12 (30.8%)
Stroke (yes/no) 9 (23.1%)
Prior diagnosis and therapy for sleep apnoea 7 (17.9%)
AHI on diagnostic study [1/h] 48.0 (33.0–69.5)
CAI on diagnostic study [1/h] 5.0 (0–9.5)*
AHI on PAP titration study [1/h] 32.5 (21.2–52.2)
CAI on PAP titration study [1/h] 21.0 (14.0–43.0)
*Twenty patients had CAI equal or greater than 5 on diagnostic study
All abbreviations in the text/Objaśnienia skrótów w tekście
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The median (interquartile range) “comparison
pressure” in the whole group (CPAP during CPAP
titrations and EPAP during BPAP-S titrations) was
8 cm H2O (7–11.5), while the median final pressu-
re attempted during the titration study was
10 cmH2O (9–12.5), with median IPAP during
BPAP-S studies of 15 cm H2O (14–17.5). Data at the
final CPAP and BPAP comparison pressure are pre-
sented in Table 2. Overall, there was no difference
in any of the polysomnographic indices on CPAP
and BPAP-S. Significant residual sleep-disordered
breathing was seen on either modality at the com-
parison pressure; remaining events were classified
as mixed apnoeas. In 19 patients the use of CPAP
was associated with lower AHI at the comparison
pressure; in 20 patients the opposite was true, and
residual AHI on CPAP and BPAP-S correlated to
each other with a statistically non-significant trend
(r = 0.30, p = 0.065, Figure 1). There was a stati-
stically significant correlation between the CAIs
(r = 0.33, p=0.04) and AIs (r = 0.62, p < 0.001)
on CPAP and BPAP-S at the comparison pressure.
In order to differentially explore the patient’s
tolerance of CPAP and BPAP-S, differences of AHI,
CAI, and AI on comparison pressure were calcula-
ted. If positive, the patient had higher AHI, CAI,
and AI on BPAP-S than CPAP, and if negative the
opposite was true. Prior diagnosis of sleep apnoea
and therapy with CPAP was associated with higher
AHI (p = 0.049), but not CAI or AI, on BPAP than
on CPAP. No other demographic or polysomnogra-
phic variable correlated with the AHI difference
between the CPAP and BPAP-S (data not shown).
Thirty-four patients (87.2%) accepted PAP
therapy that was prescribed following the sleep
evaluation, and five patients refused any therapy.
Of the 34 acceptors, 21 (61.8%) were treated with
servo ventilation, 9 (26.5%) received CPAP,
2 (5.9%) were treated with autoadjusting PAP,
1 (2.9%) received BPAP in the spontaneous-timed
mode, and 1 (2.9%) was treated with autoadjusting
BPAP.  A download of the compliance device was
available on 30/34 patients; the remaining four
patients could not be contacted and were treated
as non-compliers. Average nightly use of the devi-
ce was 4.6 (2.5–6.6) hours, and the device was used
for more than 4 hours on 62% (17–94%) of nights;
compliance was not associated with individual
responses to CPAP and BPAP-S.
Discussion
Complex sleep apnoea (CompSAS) describes
an appearance of central apnoea activity in a pa-
tient with OSA upon exposure to therapy, typical-
ly PAP-based [1–3]. The exact mechanism of this
activity is unknown and probably several mecha-
nisms operate together to produce CompSAS phe-
notype. This multitude of factors contributing to
CompSAS is the probable reason for variable be-
haviour of CompSAS patients during acute testing
and longitudinal therapy with PAP in different
patient populations [6, 21, 22].
Loop gain is an engineering term describing the
general propensity of a negative feedback loop-con-
trolled system to become unstable. Systems with
low loop gain have a capacity to stabilize upon the
introduction of a destabilizing impulse, while the
systems with high loop gain tend to destabilize more
and oscillate, or “cycle”. In the respiratory system
this is reflected by oscillations between apnoeas and
hyperpnoeas, typical of periodic breathing [23].
Loop gain can be measured experimentally, but this
has requires expensive PAV technology which is not
available in a general sleep lab [19]. In our study
we attempted to differentiate patients with high and
low loop gain by using pressure support delivered
by BPAP-S after successful opening of the airway.
Prior research on patients with CompSAS ten-
dency showed that use of bilevel PAP led to a si-
gnificant worsening of central apnoea tendency
[24]. However, Johnson et al. combined in their
study segments of sleep at different CPAP and
Figure 1. Residual apnoea-hypopnoea index at comparison pressu-
re on CPAP and BPAP-S in 39 patients with complex sleep apnoea.
Solid line represents identity line. Spearman’s coefficient of correla-
tion between AHI on CPAP and BPAP-S was 0.30, p = 0.065
Rycina 1. Wskaźnik bezdechów i spłyceń oddechu (AHI) na pozio-
mie ciśnienia porównawczego u 39 chorych z zespołem złożonego
bezdechu śródsennego leczonych aparatami CPAP i BPAP-S. Linia
ciągła przedstawia linię identyczności. Współczynnik korelacji Spe-
armana pomiędzy AHI podczas leczenia CPAP i BPAP-S wyniósł
0,30, p = 0,065
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BPAP pressures, exposing their patients to either
incomplete therapy or overtreatment [3, 17, 25].
Additionally, in some patients, a third PAP moda-
lity, BPAP in the spontaneous-timed mode was
used, which may have skewed the data.
In our research, we only used one compari-
son pressure, and, contrary to our hypothesis, re-
sidual AHI, CAI, HI, or AI were not statistically
different on CPAP and BPAP-S therapy. Additio-
nally, factors that might predispose to the develop-
ment of CompSAS (low left ventricular ejection
fraction, hypocarbia) did not correlate with the
differential effect of CPAP and BPAP-S. Also, in
a subgroup analysis, none of the known risk groups
for CompSAS (opioid users, CHF patients) had
consistent, differential responses to CPAP and
BPAP. This apparent lack of the expected effect of
BPAP-S may have resulted from insufficient effects
of this modality in revealing high loop gain states.
Though theoretically plausible and seen in some
patients in an experimental setting (Dr Andrew
Wellman, Brigham and Women’s Hospital, Harvard
University, USA, personal communication), con-
stant pressure support generated by BPAP-S (unli-
ke variable and proportionate to effort, in PAV)
may not destabilize the respiration enough to pro-
duce clinically detectable oscillations of respira-
tion. The high mixed apnoea indices in our patients
may indicate that, at least in some cases, some ob-
struction persisted at the end of central events; al-
though patients with gross obstruction were exc-
luded from analysis, small amounts of airway ob-
struction may be seen at the end of central apno-
eas [26] and it may significantly alter the pheno-
type of sleep-disordered breathing, irrespective of
loop gain [27]. Alternatively, other cofactors such
as low arousal threshold may have played a larger
role in determining the frequency of sleep-disor-
dered breathing. Based on our results, and based
on relatively low correlation between the residual
AHI on CPAP and BPAP-S, it seems worthwhile to
attempt BPAP-S during testing for CompSAS in
patients with very high residual AHI on CPAP,
especially when adaptive servo technology is not
available.
The major limitation of the study is its retro-
spective character. Patients did not follow a for-
mal protocol; rather, BPAP-S was applied by do-
ctor’s orders or, in cases of poor tolerance of PAP,
as perceived by the polysomnographic technician.
We were not testing the two PAP modalities im-
mediately after each other; in some cases, CPAP
pressure was further increased to eliminate any
possibility of obstructive changes prior to the
switch to BPAP-S. Additionally, PAP modalities
were not tested in random order, and CPAP always
preceded BPAP-S. Since there may be some chan-
ge in the obstructive and central apnoea tendency
during the night, with obstructive changes predo-
minating in the earlier part of the night (spent on
CPAP in our case), and central events appearing
later at night (BPAP-S in our case), any predomi-
nance of central or complex apnoea on BPAP-S
might have been due to the systematic error [28].
Finally, low patient number may have prevented
us from seeing a statistically significant clustering
of cases with different physiologies.
In summary, in this clinical and retrospective
study, we did not see any differential effects of
CPAP and BPAP-S on complex sleep apnoea acti-
vity. Further systematic studies on the use of BPAP-
S as an inexpensive and easily available way of
assessing a patient’s loop gain, and thus a patient’s
risk of complex sleep apnoea, are warranted.
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Table 2. Polysomnographic variables of patients with complex sleep apnoea (n = 39), who were treated with both CPAP
and BPAP-S. Data are presented as medians (interquartile range). Differences between groups are statistically in-
significant
Tabela 2. Zmienne polisomnograficzne chorych z zespołem bezdechu złożonego (n = 39), którzy byli poddani leczeniu CPAP
i BPAP-S. Dane przedstawiono jako mediany (zakres międzykwartylowy). Różnice pomiędzy grupami są niezna-
mienne statystycznie
Variable CPAP BPAP-S
Time at comparison pressure [min] 19.5 (12.5–31) 17.0 (11.5–29.0)
Apnoea-hypopnea index (AHI) [1/h] 48.0 (28.5–73.5) 54.2 (30.8–68.9)
Central apnoea index (CAI) [1/h] 21.0 (11.0–52.0) 24.3 (10.7–43.6)
Hypopnoea index (HI) [1/h] 2.9 (0–6.9) 7.2 (0–18.0)
Arousal index (AI) [1/h] 41.8 (22.0–65.7) 34.3 (18.3–73.5)
All abbreviations in the text/Objaśnienia skrótów w tekście
 Tomasz Kuźniar i wsp., Use of bilevel PAP-spontaneous in complex sleep apnoea
219www.pneumonologia.viamedica.pl
References:
1. Morgenthaler T.I., Kagramanov V., Hanak V., Decker P.A. Com-
plex sleep apnea syndrome: is it a unique clinical syndrome?
Sleep 2006; 29: 1203–1209.
2. Kuzniar T.J., Kovacevic-Ristanovic R., Freedom T. Complex
sleep apnea unmasked by the use of a mandibular advance-
ment device. Sleep Breath 2011; 15: 249–252.
3. Gilmartin G.S., Daly R.W., Thomas R.J. Recognition and man-
agement of complex sleep-disordered breathing. Curr. Opin.
Pulm. Med. 2005; 11: 485–493.
4. Yaegashi H., Fujimoto K., Abe H., Orii K., Eda S., Kubo K.
Characteristics of Japanese patients with complex sleep apnea
syndrome: a retrospective comparison with obstructive sleep
apnea syndrome. Intern. Med. 2009; 48: 427–432.
5. Endo Y., Suzuki M., Inoue Y. i wsp. Prevalence of complex
sleep apnea among Japanese patients with sleep apnea syn-
drome. Tohoku J. Exp. Med. 2008; 215: 349–354.
6. Javaheri S., Smith J., Chung E. The prevalence and natural
history of complex sleep apnea.  J. Clin. Sleep Med. 2009; 5:
205–211.
7. Westhoff M., Arzt M., Litterst P. Prevalence and treatment of
central sleep apnoea emerging after initiation of continuous pos-
itive airway pressure in patients with obstructive sleep apnoea
without evidence of heart failure. Sleep Breath 2012; 16: 71–78
8. Allam J.S., Olson E.J., Gay P.C., Morgenthaler T.I. Efficacy of
adaptive servoventilation in treatment of complex and central
sleep apnea syndromes. Chest 2007; 132: 1839–1846.
9. Kuzniar T.J., Morgenthaler T.I. Treatment of complex sleep ap-
nea syndrome. Curr. Treat. Options Neurol. 2008; 10: 336–341.
10. Kuzniar T.J., Patel S., Nierodzik C., Smith L. Comparison of
two servo ventilator devices in the treatment of complex sleep
apnea. Sleep Med. 2011; 12: 538–541.
11. Walker J.M., Farney R.J., Rhondeau S.M. i wsp. Chronic opioid
use is a risk factor for the development of central sleep apnea
and ataxic breathing. J. Clin. Sleep Med. 2007; 3: 455–461.
12. Kuna S.T., McCarthy M.P., Smickley J.S. Laryngeal response to
passively induced hypocapnia during NREM sleep in normal
adult humans. J. Appl. Physiol. 1993; 75: 1088–1096.
13. Badr M.S., Skatrud J.B., Simon P.M., Dempsey J.A. Effect of hy-
percapnia on total pulmonary resistance during wakefulness and
during NREM sleep. Am. Rev. Respir. Dis. 1991; 144: 406–414.
14. Bradley T.D., Logan A.G., Kimoff R.J. i wsp. Continuous posi-
tive airway pressure for central sleep apnea and heart failure.
N. Engl. J. Med. 2005; 353: 2025–2033.
15. Randerath W.J. Treatment options in Cheyne-Stokes respira-
tion. Therapeutic advances in respiratory disease 2010; 4:
341–351.
16. Kuzniar T.J., Kasibowska-Kuzniar K. [Complex sleep apnea syn-
drome]. Pneumonol. Alergol. Pol. 2007; 75: 370–374.
17. Thomas R.J., Terzano M.G., Parrino L., Weiss J.W. Obstruc-
tive sleep-disordered breathing with a dominant cyclic alter-
nating pattern — a recognizable polysomnographic variant
with practical clinical implications. Sleep 2004; 27:
229–234.
18. Younes M. Proportional assist ventilation, a new approach to
ventilatory support. Theory. Am. Rev. Respir. Dis. 1992; 145:
114–120.
19. Wellman A., Malhotra A., Jordan A.S., Stevenson K.E., Gautam
S., White D.P. Effect of oxygen in obstructive sleep apnea: role
of loop gain. Respir Physiol Neurobiol 2008; 162: 144–151.
20. Kuzniar T.J., Golbin J.M., Morgenthaler T.I. Moving beyond
empiric continuous positive airway pressure (CPAP) trials for
central sleep apnea: a multi-modality titration study. Sleep
Breath 2007; 11: 259–266.
21. Kuzniar T.J., Pusalavidyasagar S., Gay P.C., Morgenthaler T.I.
Natural course of complex sleep apnea-a retrospective study.
Sleep Breath 2008; 12: 135–139.
22. Dernaika T., Tawk M., Nazir S., Younis W., Kinasewitz G.T.
The significance and outcome of continuous positive airway
pressure-related central sleep apnea during split-night sleep
studies. Chest 2007; 132: 81–87.
23. White D.P. Pathogenesis of obstructive and central sleep apnea.
Am. J. Respir. Crit. Care Med. 2005; 172: 1363–1370.
24. Johnson K.G., Johnson D.C. Bilevel positive airway pressure
worsens central apneas during sleep. Chest 2005; 128: 2141–
–2150.
25. Hamilton R.D., Winning A.J., Horner R.L., Guz A. The effect of
lung inflation on breathing in man during wakefulness and
sleep. Respir. Physiol. 1988; 73: 145–154.
26. Iber C., Davies S.F., Chapman R.C., Mahowald M.M. A possible
mechanism for mixed apnea in obstructive sleep apnea. Chest
1986; 89: 800–805.
27. Wellman A., Jordan A.S., Malhotra A. i wsp. Ventilatory con-
trol and airway anatomy in obstructive sleep apnea. Am. J.
Respir. Crit. Care Med. 2004; 170: 1225–1232.
28. Tkacova R., Niroumand M., Lorenzi-Filho G., Bradley T.D.
Overnight shift from obstructive to central apneas in patients
with heart failure: role of PCO2 and circulatory delay. Circula-
tion 2001; 103: 238–243.
